Last updated: September 5, 2026
Allopurinol and lesinurad occupied different positions in gout treatment. Allopurinol was a mature, low-cost generic xanthine oxidase inhibitor. Lesinurad was a patented urate reabsorption inhibitor developed as an add-on for patients who remained above serum urate targets despite allopurinol or febuxostat. The fixed-dose combination, marketed as Duzallo, received FDA approval in 2017.
The commercial strategy failed to achieve scale. Lesinurad had a narrow label, renal safety restrictions, strong generic competition from allopurinol, limited physician adoption, and a reimbursement profile that was difficult to sustain. Ironwood Pharmaceuticals discontinued Zurampic and Duzallo in the United States in 2019. AstraZeneca withdrew lesinurad from several markets, including the European Union. Allopurinol remains widely marketed as a generic, while lesinurad has no meaningful active U.S. commercial market.
What are allopurinol and lesinurad used for?
Allopurinol reduces uric acid production by inhibiting xanthine oxidase. It is a first-line urate-lowering therapy for chronic gout and hyperuricemia. Its long market history, generic availability, broad dosing range, and low cost have made it the foundation of gout treatment.
Lesinurad inhibits URAT1, a renal transporter responsible for uric acid reabsorption. It was designed to increase urinary uric acid excretion when a xanthine oxidase inhibitor alone did not adequately control serum urate.
The FDA approved:
| Product |
Active ingredients |
FDA approval |
Indication |
Commercial status |
| Allopurinol |
Allopurinol |
Historical approval |
Chronic gout and hyperuricemia |
Generic and widely available |
| Zurampic |
Lesinurad |
Dec. 22, 2015 |
Add-on to an xanthine oxidase inhibitor |
U.S. commercialization discontinued |
| Duzallo |
Lesinurad/allopurinol |
Aug. 31, 2017 |
Fixed-dose add-on treatment for gout |
U.S. commercialization discontinued |
Zurampic was approved only for use with an xanthine oxidase inhibitor, not as monotherapy. Duzallo combined lesinurad with either 200 mg or 300 mg of allopurinol and supplied 200 mg of lesinurad per tablet (FDA, 2015, 2017).
How did the allopurinol-lesinurad market develop?
The market opportunity was based on a recognized treatment gap. Many gout patients fail to reach serum urate targets with allopurinol alone because of inadequate titration, poor adherence, renal impairment, intolerance, or disease severity. Lesinurad was intended to address patients with persistent hyperuricemia despite xanthine oxidase inhibitor therapy.
The commercial proposition faced four structural constraints:
- Allopurinol was inexpensive and familiar.
- Lesinurad required combination use and did not replace first-line therapy.
- The clinical benefit was incremental rather than transformative.
- The FDA label carried significant renal safety warnings.
The label warned about acute renal failure, particularly when lesinurad was used without an xanthine oxidase inhibitor or at higher doses. The drug was contraindicated in severe renal impairment, end-stage renal disease, kidney transplant recipients, or dialysis patients. These restrictions reduced the addressable population and complicated prescribing.
Febuxostat created a second competitive barrier. Although more expensive than generic allopurinol, febuxostat offered an alternative xanthine oxidase inhibitor for patients who could not tolerate or adequately respond to allopurinol. Probenecid remained another uricosuric alternative, while pegloticase served patients with severe refractory gout.
What was the financial trajectory of Zurampic and Duzallo?
Lesinurad did not develop into a material revenue-producing franchise for Ironwood. The products generated limited commercial revenue after launch, and the company ultimately stopped U.S. promotion and distribution.
Commercial timeline
| Year |
Event |
Financial implication |
| 2015 |
FDA approves Zurampic |
Establishes the lesinurad franchise |
| 2016 |
U.S. commercial launch |
Initial uptake remains limited |
| 2017 |
FDA approves Duzallo |
Adds a fixed-dose combination product |
| 2017-2018 |
Ironwood markets both products |
Sales remain below commercial expectations |
| 2019 |
Ironwood discontinues Zurampic and Duzallo in the U.S. |
Ends U.S. commercial investment |
| 2019-2020 |
European and other market withdrawals proceed |
Narrows global revenue opportunity |
Ironwood’s public filings described limited uptake and the decision to discontinue commercial activities after the products failed to meet commercial expectations (Ironwood Pharmaceuticals, 2019). Lesinurad revenue never approached the scale associated with major specialty pharmaceutical launches. Its financial contribution was small relative to Ironwood’s principal commercial asset, Linzess.
The fixed-dose Duzallo product did not solve the core market problem. It simplified administration but preserved lesinurad’s safety limitations and price premium. Physicians could prescribe generic allopurinol separately and reserve additional therapy for patients with persistent disease, limiting the value of a branded combination.
When did allopurinol lose exclusivity?
Allopurinol is long off patent in the United States and other major markets. Its active ingredient, immediate-release tablets, and common dosage strengths are supplied by multiple generic manufacturers.
No meaningful U.S. market exclusivity protects ordinary allopurinol tablets. Commercial competition is based on manufacturing cost, wholesaler contracts, pharmacy placement, supply reliability, and regulatory compliance rather than innovator patent rights.
Allopurinol’s commercial position is therefore the inverse of lesinurad’s:
| Factor |
Allopurinol |
Lesinurad |
| Patent position |
Mature generic |
Historically patented branded product |
| Pricing |
Low-cost generic |
Branded specialty pricing |
| Treatment role |
First-line therapy |
Add-on therapy |
| FDA market status |
Active generic market |
No meaningful active U.S. commercial market |
| Generic entry risk |
Already realized |
Commercial launch already withdrawn |
| Revenue profile |
High volume, low unit price |
Low volume, higher unit price |
What patents protected lesinurad and Duzallo?
Lesinurad’s intellectual-property position was centered on the active pharmaceutical ingredient, pharmaceutical compositions, dosing regimens, and combination use with xanthine oxidase inhibitors. Duzallo added protection directed to the fixed-dose allopurinol-lesinurad formulation and its use in gout.
The relevant patent categories were:
Lesinurad compound patents
These covered the chemical entity and related pharmaceutical forms. Compound patents generally provided the earliest and strongest period of exclusivity, subject to patent-term adjustment, patent-term extension, jurisdictional validity, and Orange Book listing practices.
Method-of-use patents
Method patents covered the use of lesinurad with allopurinol or another xanthine oxidase inhibitor to reduce serum urate in gout patients. Because lesinurad was not approved as monotherapy, combination-use claims were commercially important.
Formulation and fixed-dose combination patents
Duzallo’s protection focused on compositions combining lesinurad with allopurinol in defined strengths and dosage forms. These patents could delay or complicate a direct fixed-dose generic challenge even if a lesinurad-only product faced separate entry.
Manufacturing and process protection
Process patents and know-how could have protected selected intermediates, crystalline forms, impurity controls, and manufacturing routes. These rights would have been relevant to cost-efficient generic production but did not overcome the product’s limited commercial demand.
Because U.S. commercialization ended, the practical value of the residual patent estate declined. Patent duration remained legally relevant for Paragraph IV litigation and settlement analysis, but it no longer supported a growing branded revenue stream.
What was the Orange Book status of Zurampic and Duzallo?
The FDA approved Zurampic under NDA 207988 and Duzallo under NDA 209203. Their U.S. regulatory protection included listed patents and regulatory exclusivity associated with new drug approvals. The products were eligible for Hatch-Waxman litigation and Paragraph IV challenges while the relevant listings remained active.
The commercial importance of the Orange Book listings diminished after withdrawal of U.S. marketing. A listed patent can continue to affect generic approval timing, but a discontinued product with limited commercial demand offers little economic incentive for a generic applicant to incur litigation costs.
The practical market outcome was therefore driven by product withdrawal rather than a successful generic launch. No major U.S. generic lesinurad market emerged after Ironwood exited.
Were there Paragraph IV challenges to lesinurad?
The key risk for lesinurad was conventional Hatch-Waxman exposure. A generic applicant could file an abbreviated new drug application with a Paragraph IV certification alleging that listed patents were invalid, unenforceable, or not infringed.
The financial threat from a Paragraph IV challenge was limited by the product’s weak sales trajectory. Patent litigation is most valuable to a generic applicant when the reference product has substantial annual revenue. Lesinurad’s low uptake reduced the expected return from an aggressive challenge.
Publicly available commercial outcomes indicate that U.S. generic entry did not become the principal cause of the product’s market exit. Ironwood’s discontinuation decision preceded any meaningful generic erosion of the franchise.
What was the FDA regulatory status of lesinurad?
The FDA approved lesinurad only as adjunctive therapy with an xanthine oxidase inhibitor. The approved dose was 200 mg once daily. The FDA rejected the concept of lesinurad monotherapy because of renal safety concerns and limited the label accordingly.
The principal regulatory risks were:
- Acute renal failure and increased serum creatinine.
- Inappropriate use without allopurinol or febuxostat.
- Reduced suitability for patients with impaired kidney function.
- Monitoring requirements that complicated routine prescribing.
- A restricted position after failure or inadequate response to first-line therapy.
These restrictions reduced the drug’s potential use in the broader gout population. The safety profile also weakened payer and physician willingness to use lesinurad before lower-cost alternatives.
Which companies challenged or competed with allopurinol and lesinurad?
The competitive field included established products rather than a single direct rival.
| Competitor |
Company or supplier base |
Mechanism |
Competitive effect |
| Generic allopurinol |
Multiple manufacturers |
Xanthine oxidase inhibition |
Dominant low-cost first-line option |
| Uloric or generic febuxostat |
Takeda originator; generic suppliers |
Xanthine oxidase inhibition |
Alternative oral urate-lowering therapy |
| Probenecid |
Generic manufacturers |
Uricosuric |
Older oral add-on or alternative |
| Krystexxa |
Horizon Therapeutics, now part of Amgen |
Pegloticase enzyme therapy |
Refractory gout segment |
| Colchicine |
Multiple manufacturers |
Anti-inflammatory |
Treats flares, not chronic urate reduction |
| Lesinurad |
AstraZeneca and Ironwood |
URAT1 inhibition |
Discontinued commercial franchise |
Febuxostat became a more relevant competitor after generic entry. Its cardiovascular safety history, including the FDA boxed warning following the CARES trial, affected prescribing but did not eliminate its role. Pegloticase targeted a different, highly refractory patient population and was not a direct substitute for standard oral urate-lowering therapy.
How strong was the patent estate for allopurinol and lesinurad?
Allopurinol had negligible residual composition-of-matter protection but retained strong market defensibility through cost, manufacturing scale, physician familiarity, and broad generic distribution.
Lesinurad had a stronger historical patent position but a weaker commercial position. The patent estate could protect the branded product during the launch period, yet the drug’s limited label and safety concerns prevented the exclusivity from translating into substantial value.
The strategic distinction is important:
- Allopurinol had weak patent protection but durable market power from generic economics.
- Lesinurad had stronger patent protection but limited demand and a narrow treatment role.
- Duzallo added formulation convenience but did not materially expand the clinical market.
- Patent barriers could delay a generic product, but they could not create prescribing demand.
What generic launch risks exist for allopurinol and lesinurad?
Allopurinol faces no conventional generic-launch risk because generic competition is already established. The principal risks are supply interruptions, manufacturing observations, raw-material concentration, and price compression.
Lesinurad faced a different risk profile. A generic applicant would have needed to address:
- Listed compound or formulation patents.
- Method-of-use claims.
- The requirement to use the product with a xanthine oxidase inhibitor.
- Bioequivalence for the relevant dosage form.
- Limited commercial demand after brand withdrawal.
- Potential regulatory and labeling complications associated with renal safety.
The absence of a sizeable active branded market substantially reduced the incentive for a generic launch.
How does the allopurinol-lesinurad combination compare with other gout therapies?
Duzallo was clinically rational for patients who remained uncontrolled on allopurinol, but it was commercially disadvantaged against generic titration and alternative therapies.
| Attribute |
Duzallo |
Generic allopurinol |
Febuxostat |
Pegloticase |
| Treatment stage |
Add-on |
First-line |
Alternative oral therapy |
Refractory disease |
| Administration |
Oral fixed-dose |
Oral |
Oral |
Intravenous |
| Cost position |
Branded |
Lowest-cost |
Generic or branded |
High-cost specialty |
| Renal concerns |
Material |
Dose adjustment required |
Different safety profile |
Infusion and immunogenicity concerns |
| Commercial status |
Withdrawn in U.S. |
Active |
Active |
Active specialty market |
| Patent value |
Historical combination estate |
Minimal |
Reduced after generic entry |
Product-specific biologic estate |
What licensing deals affected lesinurad?
Lesinurad originated with Ardea Biosciences, which AstraZeneca acquired in 2012. AstraZeneca later partnered with Ironwood Pharmaceuticals for U.S. commercialization. Ironwood obtained U.S. commercial rights and launched Zurampic, followed by Duzallo.
The transaction structure transferred development and commercialization responsibilities but did not eliminate the underlying market constraints. After weak uptake, Ironwood ended U.S. commercialization, and AstraZeneca’s broader withdrawal strategy reduced the product’s international footprint.
What is the current commercial outlook for allopurinol and lesinurad?
Allopurinol has a stable, mature outlook. Demand is supported by the prevalence of gout, long treatment duration, guideline use, and low price. Growth is volume-driven and depends on diagnosis, adherence, titration, and access in emerging markets.
Lesinurad has no comparable growth trajectory. Its commercial outlook is effectively inactive in the United States and materially reduced internationally. Any future value would require a new commercial strategy, a differentiated safety or efficacy profile, or redevelopment of the molecule in a setting that avoids the limitations of the original label.
Key Takeaways
- Allopurinol remains a high-volume generic foundation for gout treatment.
- Lesinurad was approved as an add-on, not as monotherapy.
- Zurampic launched in 2016 and Duzallo in 2017.
- Ironwood discontinued both U.S. products in 2019 after limited uptake.
- Renal safety warnings and restricted use reduced lesinurad’s addressable market.
- Duzallo’s fixed-dose convenience did not overcome competition from inexpensive generic allopurinol.
- Lesinurad’s patent estate had historical value, but weak commercial demand reduced the economic value of exclusivity.
- No major U.S. generic lesinurad market developed after brand withdrawal.
- Allopurinol’s competitive advantage is cost and availability, not patent protection.
- Lesinurad’s financial trajectory ended with commercial withdrawal rather than patent-driven generic erosion.
FAQs About Allopurinol and Lesinurad
Is lesinurad still available in the United States?
No meaningful U.S. commercial supply remains. Ironwood discontinued Zurampic and Duzallo in 2019.
Is Duzallo the same as taking allopurinol and lesinurad separately?
Duzallo was a fixed-dose combination containing lesinurad and allopurinol. Its clinical purpose was to reduce pill burden while maintaining combination treatment.
Can lesinurad be used alone?
No. The FDA-approved label required use with a xanthine oxidase inhibitor because of renal safety concerns and insufficient support for monotherapy.
Does allopurinol still have active U.S. patents?
Ordinary allopurinol tablets are long off patent and are marketed by multiple generic manufacturers. Specific formulations or delivery technologies could have separate rights, but they do not protect the standard generic market.
Which drug is more commercially durable, allopurinol or lesinurad?
Allopurinol is substantially more commercially durable because it is inexpensive, widely available, guideline-supported, and used as first-line therapy. Lesinurad depended on a narrower add-on population and lost commercial support after weak uptake.
References
-
AstraZeneca. (2012). AstraZeneca completes acquisition of Ardea Biosciences. AstraZeneca plc.
-
European Medicines Agency. (2019). Zurampic: EPAR product information and marketing authorization history. EMA.
-
Food and Drug Administration. (2015). Zurampic prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2017). Duzallo prescribing information. U.S. Department of Health and Human Services.
-
Ironwood Pharmaceuticals, Inc. (2019). Annual report on Form 10-K for the fiscal year ended December 31, 2018. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
